

Program Dutch Biotech Event 2018

13:00 – 13:30	Registration		
13:30 – 15:15	<p><u>Plenary program</u> Welcome and introduction: Annemiek Verkamman (HollandBIO) Keynote 1: David Nicholson (Allergan), Announcement Venture Challenge winner 2018: Chrétien Herben (LifeSciences@Work) Keynote 2: Sebastian Nijman (Scenic Biotech) Keynote 3: Arthur Lahr (Kiadis Pharma)</p> <p><i>Location: 'Inn Spiratie'</i></p>		
15:15 – 15:45	Break		
	<u>Workshops</u>		
15:45 – 16:35	<p><u>1. Frontiers in science</u> Speakers: Peter de Keizer (UMC Utrecht) Arie Baak (Euretos)</p> <p>Moderator: Martine van Vugt (Genmab)</p> <p><i>Location: 'Uit Zicht'</i></p>	<p><u>2. Trends in dealmaking</u> Speaker: Roel Bulthuis (Merck Ventures)</p> <p>Moderator: Erik van den Berg (AM-Pharma)</p> <p><i>Location: 'Inn Zicht'</i></p>	<p><u>3. Patient engagement</u> Speakers Philipp Gallwitz (admedicum) Maryze Schoneveld van der Linde (Patient Centered Solutions)</p> <p>Moderator: Britt van de Ven</p> <p><i>Location: 'Inn Vorm'</i></p>
16:40 – 17:30	<p><u>4. How to sell your story</u> Speaker: Ellen Oerlemans (DSM)</p> <p>Moderator: Alexander Duyndam (Lygature)</p> <p><i>Location: 'Inn Vorm'</i></p>	<p><u>5. Fireside chat: Lessons in leadership</u> Speaker: Hans Schikan (multi board member)</p> <p>Moderator: Markwin Velders (Kite Pharma)</p> <p><i>Location: 'Inn Spiratie'</i></p>	
17:30 – 20:00	Drinks & Barbecue		

PLENARY PROGRAM

13.30 – 15.15hr - Location: 'Inn Spiratie'

13.30 – 13.35: Introduction: Annemiek Verkamman (managing director HollandBIO)

HollandBIO's Annemiek Verkamman will welcome the audience at the Dutch Biotech Event 2018.

13.35 – 14.05: Keynote 1: David Nicholson (EVP and Chief R&D Officer at Allergan)

Allergan is a bold, global pharmaceutical company, focusing on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. David Nicholson is EVP and Chief R&D Officer. He has been in research and development in the pharmaceutical industry since 1978. Previously, he served at various companies like Bayer CropScience, Merck and Schering-Plough. From 1988 to 2007, David held various leadership positions at Organon, where he most recently served as Executive Vice President R&D and was a member of the company's Executive Management Committee.

14.05 – 14.10: Announcement Venture Challenge winner 2018: Chrétien Herben (Program director at LifeSciences@Work)

This year's winner of the Venture Challenge, the coaching program for scientists to build a start-up business case based on their research results, will be announced.

14.10 – 14.40: Keynote 2: Sebastian Nijman (Founder and managing director at Scenic Biotech)

Scenic Biotech is applying a novel approach to target discovery by harnessing genetic suppressors. Powered by a proprietary technology, Scenic scientists are obtaining a unique and more comprehensive understanding of disease biology. Sebastian Nijman is founder and managing director. Sebastian currently maintains an Adjunct Group leader and Associate Professor position at the Ludwig Institute for Cancer Research at Oxford University.

14.40 – 15.15: Keynote 3: Arthur Lahr – CEO at Kiadis Pharma

Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer and more effective for patients. Their primary objective is to develop products that provide safer and more efficacious treatment options for blood cancer and blood disorder patients, improving their survival rate and quality of life. Arthur Lahr is Chief Executive Officer of Kiadis Pharma. Prior to joining Kiadis Pharma, he was Chief Strategy Officer and member of the Management Committee at Crucell from 2001 until its acquisition by Johnson & Johnson in 2011.

WORKSHOPS

Workshop 1: Frontiers in science

15.45 – 16.35h – Location: 'Uit Zicht'

Speakers:

Arie Baak (Euretos)

Peter de Keizer (UMC Utrecht and Cleara Biotech)

Moderator: Martine van Vugt (Genmab)

Ground-breaking science and innovation, that's what this workshop is all about. Two speakers show how their proprietary technologies will affect the way we look at life sciences. Euretos' Artificial Intelligence platform allows scientists to analyse data in a complete new dimension. Peter de Keizer aims to unravel the secrets of aging. What are the molecular mechanisms causing aging? Are there ways to slow down these processes? After this workshop, you'll be up-to-speed with some of the most exciting developments at the frontiers of science!

About Arie Baak (Euretos)

Arie Baak is one of the co-founders of Euretos, an AI platform used by (pre-)clinical researchers to take an in-silico, systems biology approach to the identification & validation of targets and biomarkers. For the first two decades of his career, Arie has worked in various customer facing strategic innovation roles in the mobile telecoms and internet infrastructure markets. In this high performance/high volume environment he has been developing analytics solutions that provide actionable insight to end users long before the term 'big data analytics' became fashionable. Since 2010 Arie has been applying his expertise to the life sciences where he has worked with some of the world's leading pharma, biotech and academic institutions to develop a data & AI driven approach to life sciences research.

For more information about Euretos, [click here](#).

Peter de Keizer (UMC Utrecht and Cleara Biotech)

In January 2018, Peter de Keizer joined the University Medical Center Utrecht as assistant professor. The aim of his group is to unravel the molecular mechanisms that cause cells to become senescent and to identify how these cells drive aging and age-related diseases. The role of senescence in late-stage therapy-resistant cancer is a major component of this research. The research has a strong translational component and a spearpoint of the group is to develop methods to target the deleterious effects of senescent and senescent-like cancer cells, for instance by eliminating them altogether. Ultimately, the aim is to optimize compounds that effectively eliminate the most dangerous senescent cells in human. Peter is also the scientific co-founder of Cleara Biotech, a company trying to optimize the most potent anti-senescence lead compounds in a professional manner for actual clinical translation.

For an overview of Peter de Keizer's research, [click here](#).

Workshop 2: Trends in deal-making

15.45 – 16.35hr – Location: 'Inn Zicht

Speaker:

Roel Bulthuis (Merck Ventures)

Moderator: Erik van den Berg (AM-Pharma)

Deal-making is an essential aspect of biotech entrepreneurship: no deal, no progress. Sounds easy, right? But it isn't. Preparing and closing a deal demands thorough preparation, knowledge and hard work. What kind of deals are currently fashionable? And what to expect the coming years? During this workshop, Roel Bulthuis of Merck Ventures shares some unique insights in deal-making trends.

About Roel Bulthuis

Roel Bulthuis joined the biopharmaceutical division of Merck KGaA, Darmstadt, Germany in 2006 and started the previous biopharma venture fund MS Ventures in 2009. Previously, Roel was a Director in the Biotech Investment Banking Team at Fortis Bank, where he was responsible for the origination and execution of a wide range of financing and strategic transactions in the biotech sector based out of Amsterdam and New York. Before joining Fortis Bank, Roel worked at Devgen NV in Gent, Belgium, as a business analyst. Roel holds a Msc. in Biopharmaceutical Sciences from Leiden University, the Netherlands, and an MBA in Finance from the Helsinki School of Economics, Finland. Roel is based in Amsterdam.

For more information about Merck Ventures, [click here](#).

Workshop 3: Patient engagement

15.45 – 16.35hr – Location 'Inn Vorm'

Speakers:

Philipp Gallwitz (admedicum® Business for Patients)

Maryze Schoneveld van der Linde (Patient Centered Solutions)

Moderator: Britt van de Ven (HollandBIO)

Including patient expertise during the entire product lifecycle is key for truly patient-focused innovative products and services. It is instrumental for successful business. But how can you put theory into practice? This workshop gives you an interactive sneak-peak into the do's and don'ts of early stage patient engagement, by people who know the ropes.

About Philipp Gallwitz

Philipp is Founder and Managing Partner of admedicum®, a unique group of European patient engagement experts. admedicum® was founded on the conviction that biopharma has to integrate patients as key stakeholders into the learning and decision making process along the value chain. However partnering with patients is complex and new to many. admedicum® specializes exclusively on helping companies with identifying valuable opportunities to work with patients and making it happen.

For more information about admedicum, [click here](#).

About Maryze Schoneveld van der Linde

Maryze is an award-winning international patient advocate with an extensive network in the rare disease field. She is an expert by experience – following her diagnosis with Pompe Disease at the age of eight – and a champion in patient engagement and empowerment. With her own consultancy firm Patient Centered Solutions, Maryze provides the patient perspective to industry, with a special focus on the patient journey and clinical development. Maryze is also a Patient Expert Partner at admedicum®.

For more information about Patient Centered Solutions, [click here](#).

Workshop 4: How to sell your story

16.40 – 17.30hr – Location: 'Inn Vorm'

Speaker:

Ellen Oerlemans (DSM)

Moderator: Alexander Duyndam (Lygature)

Not every biotech entrepreneur is capable of translating ground-breaking science and innovation into something understandable for a broader audience. This workshop not only tells you why it is important to tell your story, it teaches you to nail this, too! During the workshop, Ellen Oerlemans of DSM will share the company's new strategy, with emphasis on the way to communicate it. In addition, plenty of tips and tricks will be shared, upgrading your skillset from telling a story to selling a story.

About Ellen Oerlemans

Ellen works as Manager Public Affairs and Corporate Affairs at DSM in the Netherlands. DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in Life Sciences and Materials Sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials.

For more information about DSM, [click here](#).

Workshop 5: Fireside chat: Lessons in leadership

16.40 – 17.30hr – Location: 'Inn Spiratie'

Speaker:

Hans Schikan (multi board member)

Moderator: Markwin Velders (Kite Pharma)

During this fireside chat, HollandBIO chairman Markwin Velders will ask seasoned entrepreneur Hans Schikan to share his biotech secrets, including all ups and downs of his impressive career. What makes a successful biotech entrepreneur? Is making mistakes really the best and only way to learn? Join the workshop and seize this opportunity to ask multi-board member and biotech guru Hans Schikan everything you want to know.

About Hans Schikan

Hans Schikan is former CEO of Prosensa, a biopharmaceutical company, which was acquired by BioMarin early 2015. He currently serves on the boards and advisory councils of several listed and private life sciences companies.